Biological age reversal, epigenetic clocks, senolytics, and anti-aging interventions
1,805 articles
A systematic review of ~100 studies reveals animal protein excels for hypertrophy but accelerates aging through mTOR, IGF-1, and inflammation.
New research links metabolomic aging, smoking cessation, and repurposed drugs to dementia risk — plus estrogen's role in post-menopausal memory loss.
VERVE-102 permanently silences the PCSK9 gene in a single dose, slashing LDL cholesterol up to 62% with encouraging early safety data.
Texas A&M researchers developed a nasal spray using extracellular vesicles that reversed brain aging, restored memory, and cut inflammation in just two doses.
Paris-based Lucis uses AI and blood biomarker panels to flag sub-clinical risks early, with 75% of users improving key markers in six months.
Sam Altman-backed Retro Biosciences hits $1.8B valuation as its first human trial targeting Alzheimer's protein buildup shows early promise.
Daewoong Pharmaceutical buys Turn Bio's ERA platform, using mRNA to partially reverse cellular aging without tumor risk.
Industry leaders at Milan 2026 say longevity medicine must move beyond hype and deliver measurable, accountable preventive care.
UC Berkeley researchers expose critical incoherence in DNA methylation age clocks, showing up to 54% of their features contradict actual biological trends.
First RCT evidence that semaglutide significantly reduces epigenetic age across multiple validated clocks in people with HIV-associated lipohypertrophy.
A 234-patient study shows lecanemab is feasible in specialty clinics, with ARIA occurring in 22% but severe events in only 1% of patients.
Scientists identify MRAP as a key molecular driver of thymic fat replacement, linking thymosin-α1 and FoxO1 signaling to immune aging.
